These results suggest that mainly targeting the previously described interplay between the DNA methylating machinery and the MYC-driven tumor maintenance [52] causes the anti-cancer effects of decitabine in T-ALL and T-LBL. This evidence concerns the gene MYC and acute lymphoblastic leukemia.